INmune Bio Inc INMB
News
INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th
INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
INmune Bio to Attend the 2026 Maxim Growth Summit
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

